Cargando…
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, pso...
Autor principal: | Reimold, Andreas M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045097/ https://www.ncbi.nlm.nih.gov/pubmed/27790010 http://dx.doi.org/10.2147/OARRR.S14569 |
Ejemplares similares
-
Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions
por: Marzan, Katherine Anne B
Publicado: (2012) -
Long-term use of adalimumab in the treatment of rheumatic diseases
por: Papagoras, Charalampos, et al.
Publicado: (2009) -
Hydroxychloroquine in rheumatic autoimmune disorders and beyond
por: Nirk, Eliise Laura, et al.
Publicado: (2020) -
Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases
por: Pizano-Martinez, Oscar, et al.
Publicado: (2023) -
Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis
por: Hedar, Ahmed M., et al.
Publicado: (2021)